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BACKGROUND
In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous 
coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death 
or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of 
such events is unclear.
METHODS
We randomly assigned patients with STEMI and multivessel coronary artery disease who 
had undergone successful culprit-lesion PCI to a strategy of either complete revascular-
ization with PCI of angiographically significant nonculprit lesions or no further revas-
cularization. Randomization was stratified according to the intended timing of noncul-
prit-lesion PCI (either during or after the index hospitalization). The first coprimary 
outcome was the composite of cardiovascular death or myocardial infarction; the second 
coprimary outcome was the composite of cardiovascular death, myocardial infarction, 
or ischemia-driven revascularization.
RESULTS
At a median follow-up of 3 years, the first coprimary outcome had occurred in 158 of the 
2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 
2025 patients (10.5%) in the culprit-lesion-only PCI group (hazard ratio, 0.74; 95% confi-
dence interval [CI], 0.60 to 0.91; P = 0.004). The second coprimary outcome had occurred 
in 179 patients (8.9%) in the complete-revascularization group as compared with 339 pa-
tients (16.7%) in the culprit-lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 0.61; 
P<0.001). For both coprimary outcomes, the benefit of complete revascularization was 
consistently observed regardless of the intended timing of nonculprit-lesion PCI (P = 0.62 
and P = 0.27 for interaction for the first and second coprimary outcomes, respectively).
CONCLUSIONS
Among patients with STEMI and multivessel coronary artery disease, complete revascu-
larization was superior to culprit-lesion-only PCI in reducing the risk of cardiovascular 
death or myocardial infarction, as well as the risk of cardiovascular death, myocardial 
infarction, or ischemia-driven revascularization. (Funded by the Canadian Institutes of 
Health Research and others; COMPLETE ClinicalTrials.gov number, NCT01740479.)
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P
rimary percutaneous coronary in-
tervention (PCI) is the preferred method of 
reperfusion for patients with ST-segment 
elevation myocardial infarction (STEMI).1-4 These 
patients often have multivessel coronary artery 
disease, with additional angiographically signifi-
cant lesions in locations separate from that of the 
culprit lesion that caused the acute event.5 Whether 
to routinely revascularize these nonculprit lesions 
or to manage them conservatively with guideline-
based medical therapy alone is a common dilem-
ma.6-8 Nonculprit lesions, which are usually discov-
ered incidentally at the time of primary PCI, may 
represent stable coronary artery plaques, for 
which additional revascularization may not offer 
additional benefit.9 However, if nonculprit lesions 
have morphologic features consistent with un-
stable plaques, which confer an increased risk of 
future cardiovascular events, there may be a bene-
fit of routine nonculprit-lesion PCI.10,11
Although observational studies have suggested 
a possible reduction in clinical events with 
staged nonculprit-lesion PCI,12,13 these studies 
are limited by selection bias and confounding. 
Randomized trials have shown reductions in the 
risk of composite outcomes with nonculprit-lesion 
PCI, with results driven predominantly by the 
decreased risk of subsequent revascularization 
with that strategy.14-17 Meta-analyses suggest a 
reduction in the risk of death from cardiovascu-
lar causes or myocardial infarction with noncul-
prit-lesion PCI,18-20 but previous individual trials 
have not had the power to examine this clini-
cally important outcome. The Complete versus 
Culprit-Only Revascularization Strategies to Treat 
Multivessel Disease after Early PCI for STEMI 
(COMPLETE) trial was designed to address this 
evidence gap.
Me thods
Trial Design and Oversight
The COMPLETE trial was a multinational, ran-
domized trial that evaluated a strategy of com-
plete revascularization (consisting of PCI of all 
suitable nonculprit lesions) as compared with a 
strategy of no further revascularization in pa-
tients with STEMI and multivessel coronary ar-
tery disease who had undergone successful culprit-
lesion PCI.21 The executive committee designed 
the protocol, which is available with the full text 
of this article at NEJM.org, and was responsible 
for the conduct and oversight of the trial. The 
trial was coordinated and sponsored by the 
Population Health Research Institute of Hamil-
ton Health Sciences and McMaster University. 
The trial was funded by the Canadian Institutes 
of Health Research. AstraZeneca and Boston 
Scientific provided additional funding. These 
companies had no role in the trial design; col-
lection, analysis, or interpretation of the data; or 
writing of the manuscript. The protocol was 
approved by institutional review boards at all 
trial centers. The authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol.
Eligibility
Patients who presented to the hospital with 
STEMI were considered for inclusion in the trial 
if they could undergo randomization within 72 
hours after successful culprit-lesion PCI. Eligible 
patients were required to have multivessel coro-
nary artery disease, defined as the presence of 
at least one angiographically significant non–
infarct-related (nonculprit) lesion that was ame-
nable to successful treatment with PCI and was 
located in a vessel with a diameter of at least 
2.5 mm that was not stented as part of the index 
culprit-lesion PCI. Nonculprit lesions were deemed 
angiographically significant if they were associat-
ed with at least 70% stenosis of the vessel diameter 
on visual estimation or with 50 to 69% stenosis 
accompanied by a fractional f low reserve (FFR) 
measurement of 0.80 or less. The main exclusion 
criteria were an intention before randomization 
to revascularize a nonculprit lesion, a planned 
surgical revascularization, or previous coronary-
artery bypass grafting surgery. Details regarding 
inclusion and exclusion criteria are provided in 
Table S1 in the Supplementary Appendix, avail-
able at NEJM.org. Written informed consent was 
obtained from all the patients.
Randomization and Trial Treatments
Eligible patients were randomly assigned to under-
go either complete revascularization or culprit-
lesion-only revascularization according to a 
computer-generated randomization list with the 
use of randomly permuted blocks and with blind-
ing to trial center. Randomization was stratified 
according to center and the intended timing of 
nonculprit-lesion PCI (if the patient were to be 
assigned to the complete-revascularization group). 
Randomization was performed as soon as pos-
sible (no later than 72 hours) after the index PCI.
A Quick Take is 
available at 
NEJM.org 
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Patients who were randomly assigned to the 
complete-revascularization strategy were to have 
routine staged PCI (i.e., PCI during a procedure 
separate from the index PCI procedure for STEMI) 
of all suitable nonculprit lesions, regardless of 
whether there were clinical symptoms or there 
was evidence of ischemia. Investigators specified 
before randomization whether they intended to 
perform nonculprit-lesion PCI during the index 
hospitalization or after hospital discharge (no 
later than 45 days after randomization). Evero-
limus-eluting stents were strongly recommended 
for all PCI procedures. It was recommended that 
PCI of chronic total occlusions be attempted 
only by operators who had experience in treating 
chronic total occlusions and only when there 
was a high likelihood of successful PCI.
Patients who were randomly assigned to the 
culprit-lesion-only PCI strategy received guide-
line-based medical therapy with no further re-
vascularization, regardless of whether there was 
evidence of ischemia on noninvasive testing. 
Protocol-specified criteria for crossover to the 
complete-revascularization strategy are provided 
in the Supplementary Appendix.
All coronary angiograms obtained during the 
trial were forwarded to an angiographic core 
laboratory located at the Population Health Re-
search Institute for detailed assessment.21 After 
initial hospital discharge, routine follow-up oc-
curred at 6 weeks, 6 months, 1 year, and yearly 
thereafter up to the final follow-up visit.
Recommended Medical Therapy
Guideline-based medical therapy was recommend-
ed in both treatment groups. Dual antiplatelet 
therapy with aspirin and ticagrelor for at least 
1 year was recommended.22 Beyond 1 year, aspirin 
was recommended for all patients, and ticagrelor 
(60 mg twice daily) was recommended for pa-
tients who were not at high risk for bleeding.23 
High-dose statin therapy, angiotensin-converting–
enzyme inhibitors or angiotensin-receptor block-
ers, mineralocorticoid-receptor antagonists, and 
beta-blockers were recommended.21
Outcomes
The first coprimary outcome was the composite 
of death from cardiovascular causes or new myo-
cardial infarction; the second coprimary outcome 
was the composite of death from cardiovascular 
causes, new myocardial infarction, or ischemia-
driven revascularization. Safety outcomes includ-
ed major bleeding and contrast-associated acute 
kidney injury. Secondary outcomes are described 
in the Supplementary Appendix; detailed defini-
tions of all outcomes are provided in Table S2 in 
the Supplementary Appendix. Myocardial infarc-
tion was defined according to the third universal 
definition and was subclassified according to 
type.24 An event-adjudication committee, which 
consisted of clinicians who were unaware of the 
treatment assignments, adjudicated primary, sec-
ondary, and safety outcome events.
Statistical Analysis
We estimated that a sample of 4000 patients 
would give the trial 80% power to detect a 22% 
lower risk of the composite of cardiovascular 
death or myocardial infarction in the complete-
revascularization group than in the culprit-lesion-
only PCI group, assuming an event rate of 5% 
per year in the culprit-lesion-only PCI group. To 
preserve the overall type I error rate of 5% for 
the testing of both coprimary outcomes, the 
first coprimary outcome was tested at a P value 
of 0.045 and the second at a P value of 0.0119.21 
One interim analysis was performed. Because a 
very conservative monitoring boundary was used 
for this analysis, no adjustment of the type I error 
threshold was applied. Details regarding these 
analyses are provided in the Supplementary Ap-
pendix.
All patients who underwent randomization 
were included in the analysis according to the 
treatment group to which they were assigned, 
regardless of the treatment they actually received 
(intention-to-treat principle). The coprimary out-
comes were analyzed with the use of a time-to-
first-event approach. Estimates of the hazard 
ratios and 95% confidence intervals were calcu-
lated with the use of Cox proportional-hazards 
models, with treatment group as an independent 
variable and with stratification according to the 
intended timing of nonculprit-lesion PCI. Confi-
dence intervals for secondary and exploratory 
efficacy outcomes have not been adjusted for 
multiple comparisons, and therefore inferences 
drawn from these intervals may not be reproduc-
ible. The two treatment groups were compared 
with the use of the stratified log-rank test. Cumu-
lative incidence was estimated with the Kaplan–
Meier method. A sensitivity analysis was per-
formed with a Fine–Gray model to account for 
the competing risk of death from noncardiovas-
cular causes.25
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R esult s
Patients, Treatment, and Follow-up
From February 1, 2013, through March 6, 2017, 
a total of 4041 patients from 140 centers in 31 
countries underwent randomization: 2016 were 
assigned to the complete-revascularization group 
and 2025 to the culprit-lesion-only PCI group. 
Baseline and procedural characteristics are shown 
in Tables 1 and 2, respectively. Details are pro-
vided in Table S3 and Figure S1 in the Supple-
mentary Appendix.
Among the patients who underwent complete 
revascularization, the median time from ran-
domization to nonculprit-lesion PCI was 1 day 
(interquartile range, 1 to 3) among the 1285 
patients for whom the intended timing of non-
culprit-lesion PCI was during the index hospital-
ization and 23 days (interquartile range, 12.5 to 
33.5) among the 596 patients for whom the in-
Characteristic
Complete 
Revascularization 
(N = 2016)
Culprit-Lesion-Only 
PCI 
(N = 2025)
Age — yr 61.6±10.7 62.4±10.7
Male sex — no. (%) 1623 (80.5) 1602 (79.1)
Diabetes — no. (%) 385 (19.1) 402 (19.9)
Chronic renal insufficiency — no./total no. (%) 37/1884 (2.0) 44/1903 (2.3)
Previous myocardial infarction — no. (%) 148 (7.3) 154 (7.6)
Current smoker — no. (%) 819 (40.6) 787 (38.9)
Hypertension — no. (%) 982 (48.7) 1027 (50.7)
Dyslipidemia — no. (%) 764 (37.9) 797 (39.4)
Previous PCI — no. (%) 142 (7.0) 141 (7.0)
Previous stroke — no. (%) 64 (3.2) 62 (3.1)
Time from symptom onset to index PCI — no./total no. (%)
<6 hr 1383/1994 (69.4) 1341/2000 (67.0)
6 to 12 hr 322/1994 (16.1) 354/2000 (17.7)
>12 hr 289/1994 (14.5) 305/2000 (15.2)
Killip class ≥II — no./total no. (%) 212/1995 (10.6) 218/1996 (10.9)
Glycated hemoglobin — % 6.3±1.6 6.3±1.6
Low‑density lipoprotein cholesterol — mmol/liter 3.1±1.2 3.1±1.2
Peak creatinine — μmol/liter 84.7±30.8 85.2±26.8
Medications at discharge — no. (%)
Aspirin 2011 (99.8) 2015 (99.5)
P2Y12 inhibitor
Any 2003 (99.4) 2018 (99.7)
Ticagrelor 1298 (64.4) 1281 (63.3)
Prasugrel 193 (9.6) 169 (8.3)
Clopidogrel 516 (25.6) 572 (28.2)
Beta‑blocker 1776 (88.1) 1804 (89.1)
Angiotensin‑converting–enzyme inhibitor or angiotensin‑ 
receptor blocker
1723 (85.5) 1714 (84.6)
Statin 1980 (98.2) 1968 (97.2)
*  Plus–minus values are means ±SD. To convert the values for low‑density lipoprotein cholesterol to milligrams per deci‑
liter, divide by 0.02586. To convert the values for creatinine to milligrams per deciliter, divide by 88.4. PCI denotes per‑
cutaneous coronary intervention.
Table 1. Characteristics of the Patients at Baseline.*
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Characteristic
Complete 
Revascularization 
(N = 2016)
Culprit-Lesion-Only 
PCI 
(N = 2025)
Index procedure for STEMI — no. (%)
Primary PCI 1853 (91.9) 1885 (93.1)
Pharmacoinvasive PCI 64 (3.2) 61 (3.0)
Rescue PCI 99 (4.9) 79 (3.9)
Radial access — no. (%) 1629 (80.8) 1634 (80.7)
Thrombus aspiration — no./total no. (%) 451/1864 (24.2) 481/1875 (25.7)
SYNTAX score†‡
Culprit lesion–specific score 8.8±5.3 8.6±5.3
Nonculprit lesion–specific score 4.6±2.8 4.6±2.7
Baseline score, including culprit lesion 16.3±6.8 16.0±6.6
Residual score, after index PCI 7.2±4.9 7.0±4.7
Location of culprit lesion — no./total no. (%)†
Left main coronary artery 3/1918 (0.2) 4/1940 (0.2)
Left anterior descending artery 660/1918 (34.4) 657/1940 (33.9)
Circumflex artery 346/1918 (18.0) 307/1940 (15.8)
Right coronary artery 909/1918 (47.4) 972/1940 (50.1)
No. of residual diseased vessels — no./total no. (%)†
1 1458/1917 (76.1) 1492/1934 (77.1)
≥2 459/1917 (23.9) 442/1934 (22.9)
Location of nonculprit lesions — no./total no. of lesions (%)†
Left main coronary artery 10/2731 (0.4) 3/2624 (0.1)
Left anterior descending artery 1037/2731 (38.0) 1080/2624 (41.2)
Proximal 267/2731 (9.8) 274/2624 (10.4)
Middle 592/2731 (21.7) 621/2624 (23.7)
Circumflex artery 993/2731 (36.4) 933/2624 (35.6)
Proximal left circumflex artery, obtuse marginal branch,  
and ramus intermedius artery
744/2731 (27.2) 697/2624 (26.6)
Distal left circumflex artery and posterior left ventricular branch 249/2731 (9.1) 236/2624 (9.0)
Right coronary artery 691/2731 (25.3) 608/2624 (23.2)
Diameter of vessel with nonculprit lesion — mm† 2.8±0.5 2.9±0.6
Nonculprit‑lesion stenosis on visual estimation
% 79.3±8.1 78.7±7.9
No./total no. of lesions (%)
50–69%, with fractional flow reserve <0.80 21/2612 (0.8) 16/2576 (0.6)
70–79% 1078/2612 (41.3) 1162/2576 (45.1)
80–89% 875/2612 (33.5) 839/2576 (32.6)
90–99% 583/2612 (22.3) 508/2576 (19.7)
100% 55/2612 (2.1) 51/2576 (2.0)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. STEMI denotes ST‑segment 
 elevation myocardial infarction.
†  Data were obtained at the angiographic core laboratory.
‡  The SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score is used to describe the degree of angiographic 
complexity; a score of 0 indicates no angiographically significant disease, and higher scores indicate more extensive and 
complex coronary artery disease.
Table 2. Procedural Characteristics.*
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tended timing of nonculprit-lesion PCI was after 
hospital discharge. Within the first 45 days, 
crossover from the culprit-lesion-only PCI group 
to the complete-revascularization group occurred 
in 96 patients (4.7%), and crossover from the 
complete-revascularization group to the culprit-
lesion-only PCI group occurred in 78 patients 
(3.9%). After nonculprit-lesion PCI, 90.1% of the 
patients in the complete-revascularization group 
had a SYNTAX (Synergy between PCI with Taxus 
and Cardiac Surgery) score of 0, indicating no 
angiographically significant disease (i.e., complete 
revascularization).
Outcome events were assessed up to the date 
of each patient’s final follow-up visit, which 
ranged from September 1, 2018, to June 7, 2019, 
when the database was locked. The mean follow-
up time was 36.2 months, and the median fol-
low-up time was 35.8 months (interquartile 
range, 27.6 to 44.3). Data on vital status were 
complete for 99.1% and 99.3% of the patients in 
the complete-revascularization and culprit-lesion-
only PCI groups, respectively. Data on concomi-
tant medication use at hospital discharge and 
throughout follow-up are provided in Table S4 in 
the Supplementary Appendix.
Primary and Secondary Outcomes
At a median follow-up of 3 years, death from 
cardiovascular causes or new myocardial infarc-
tion (the first coprimary composite outcome) had 
occurred in 158 patients (7.8%) in the complete-
revascularization group as compared with 213 
patients (10.5%) in the culprit-lesion-only PCI 
group (hazard ratio, 0.74; 95% confidence inter-
val [CI], 0.60 to 0.91; P = 0.004) (Table 3 and 
Fig. 1A). This result was driven by the lower inci-
dence of new myocardial infarction in the com-
plete-revascularization group than in the culprit-
lesion-only PCI group (5.4% vs. 7.9%; hazard 
ratio, 0.68; 95% CI, 0.53 to 0.86); the incidence 
of death from cardiovascular causes was 2.9% 
and 3.2%, respectively (hazard ratio, 0.93; 95% 
CI, 0.65 to 1.32). Specifically, the following types 
of myocardial infarction occurred less frequently 
in the complete-revascularization group than in 
the culprit-lesion-only PCI group: non-STEMI (66 
events vs. 105 events), new STEMI (43 vs. 53), 
and predominantly, myocardial infarction type 1 
(63 vs. 128) (Table S5 in the Supplementary Ap-
pendix).
Death from cardiovascular causes, new myo-
cardial infarction, or ischemia-driven revascular-
ization (the second coprimary composite out-
come) occurred in 179 patients (8.9%) in the 
complete-revascularization group as compared 
with 339 patients (16.7%) in the culprit-lesion-
only PCI group (hazard ratio, 0.51; 95% CI, 0.43 
to 0.61; P<0.001) (Table 3 and Fig. 1B). The re-
sults of competing-risk analyses with respect to 
the two coprimary outcomes were consistent 
with the results of the primary analyses (Table 
S6 in the Supplementary Appendix).
Death from cardiovascular causes, new myo-
cardial infarction, ischemia-driven revasculariza-
tion, unstable angina, or New York Heart Asso-
ciation class IV heart failure (the key secondary 
outcome) occurred in 272 patients (13.5%) in the 
complete-revascularization group as compared 
with 426 patients (21.0%) in the culprit-lesion-
only PCI group (hazard ratio, 0.62; 95% CI, 0.53 
to 0.72). Results for other secondary outcomes 
are shown in Table 3.
Subgroup Analyses and Timing of Nonculprit-
Lesion PCI
For the coprimary outcomes, there was no dif-
ferential treatment effect in prespecified sub-
groups (Fig. 2). The benefit of complete revas-
cularization was consistently observed among 
patients for whom the intended timing of non-
culprit-lesion PCI was during the index hospital-
ization and those for whom the intended timing 
was after hospital discharge (P = 0.62 and P = 0.27 
for interaction for the first and second copri-
mary outcomes, respectively). In 87.1% of the 
patients in the complete-revascularization group, 
the actual timing of nonculprit-lesion PCI corre-
sponded to the intended timing specified by the 
investigator before randomization. The hazard 
ratio for the first coprimary outcome with a 
complete-revascularization strategy as compared 
with a culprit-lesion-only PCI strategy was 0.77 
(95% CI, 0.59 to 1.00) in the subgroup for which 
in-hospital nonculprit-lesion PCI was intended 
and 0.69 (95% CI, 0.49 to 0.97) in the subgroup 
for which postdischarge nonculprit-lesion PCI 
was intended.
Safety and Other Outcomes
There was no significant difference between the 
two treatment groups in the risk of major bleed-
ing, stroke, or stent thrombosis (Table 3). Re-
sults for specific types of stent thrombosis are 
shown in Table S7 in the Supplementary Appen-
dix. Contrast-associated acute kidney injury oc-
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curred in 30 patients in the complete-revascular-
ization group as compared with 19 patients in 
the culprit-lesion-only PCI group (odds ratio, 1.59; 
95% CI, 0.89 to 2.84; P = 0.11). This event was 
attributed to the nonculprit-lesion PCI procedure 
in 7 patients in the complete-revascularization 
group as compared with none (in accordance 
with the protocol) in the culprit-lesion-only PCI 
group. For those 7 patients, the intended timing 
of nonculprit-lesion PCI was during the index 
hospitalization.
Discussion
The COMPLETE trial showed that, among patients 
with STEMI and multivessel coronary artery dis-
ease, a strategy of staged nonculprit-lesion PCI 
with the goal of complete revascularization re-
sulted in a 26% lower risk of a composite of 
death from cardiovascular causes or new myo-
cardial infarction at a median follow-up of 3 years 
than did a strategy of culprit-lesion-only PCI. 
This benefit was driven by the 32% lower risk of 
new, nonfatal myocardial infarction in the com-
plete-revascularization group than in the culprit-
lesion-only PCI group; the incidence of death 
from cardiovascular causes was similar in the 
two groups. For the second coprimary outcome, 
which included ischemia-driven revasculariza-
tion in addition to the other two events, the risk 
with a complete-revascularization strategy was 
approximately half the risk with a culprit-lesion-
only PCI strategy. There was no significant dif-
ference between the two groups in the risk of 
Outcome
Complete 
Revascularization 
(N = 2016)
Culprit-Lesion-Only 
PCI 
(N = 2025)
Hazard Ratio 
(95% CI) P Value
no. (%)
% per 
person-yr no. (%)
% per 
person-yr
Coprimary outcomes
Cardiovascular death or myocardial infarction 158 (7.8) 2.7 213 (10.5) 3.7 0.74 (0.60–0.91) 0.004
Cardiovascular death, myocardial infarction,  
or ischemia‑driven revascularization
179 (8.9) 3.1 339 (16.7) 6.2 0.51 (0.43–0.61) <0.001
Key secondary outcome
Cardiovascular death, myocardial infarction, 
ischemia‑driven revascularization, unsta‑
ble angina, or NYHA class IV heart failure
272 (13.5) 4.9 426 (21.0) 8.1 0.62 (0.53–0.72)
Other secondary outcomes
Myocardial infarction 109 (5.4) 1.9 160 (7.9) 2.8 0.68 (0.53–0.86)
Ischemia‑driven revascularization 29 (1.4) 0.5 160 (7.9) 2.8 0.18 (0.12–0.26)
Unstable angina 70 (3.5) 1.2 130 (6.4) 2.2 0.53 (0.40–0.71)
Death from cardiovascular causes 59 (2.9) 1.0 64 (3.2) 1.0 0.93 (0.65–1.32)
Death from any cause 96 (4.8) 1.6 106 (5.2) 1.7 0.91 (0.69–1.20)
Other outcomes
Stroke 38 (1.9) 0.6 29 (1.4) 0.5 1.31 (0.81–2.13)
NYHA class IV heart failure 58 (2.9) 1.0 56 (2.8) 0.9 1.04 (0.72–1.50)
Stent thrombosis 26 (1.3) 0.4 19 (0.9) 0.3 1.38 (0.76–2.49)
Safety outcomes
Major bleeding 58 (2.9) 1.0 44 (2.2) 0.7 1.33 (0.90–1.97) 0.15
Contrast‑associated acute kidney injury† 30 (1.5) — 19 (0.9) — 1.59 (0.89–2.84) 0.11
*  P values were calculated with the use of the stratified log‑rank test. Confidence intervals for secondary and exploratory 
efficacy outcomes have not been adjusted for multiple comparisons, and therefore inferences drawn from these inter‑
vals may not be reproducible. NYHA denotes New York Heart Association.
†  Contrast‑associated acute kidney injury was treated as a binary outcome. Shown are an odds ratio (instead of a hazard 
ratio), 95% confidence interval, and P value that were calculated with stratified logistic regression.
Table 3. Efficacy and Safety Outcomes.*
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major bleeding or stroke. The benefit of com-
plete revascularization was consistently observed 
regardless of whether nonculprit-lesion PCI was 
to be performed during the index hospitaliza-
tion or several weeks after discharge from the 
hospital.
We designed the trial to have sufficient 
power to determine whether a complete-revascu-
larization strategy would lead to a meaningful 
reduction in the risk of the clinically important 
outcome of cardiovascular death or new myocar-
dial infarction. Previous trials that evaluated a 
complete-revascularization strategy in patients 
with STEMI were smaller and included revascu-
larization as part of the composite primary out-
come.14-17 In the absence of a reduction in irre-
versible events such as cardiovascular death or 
new myocardial infarction, the clinical relevance 
of performing early nonculprit-lesion PCI in all 
patients with multivessel coronary artery disease 
to prevent later PCI in a smaller number of those 
patients is debatable. We have now found that 
routine nonculprit-lesion PCI with the goal of 
complete revascularization confers a reduction 
in the long-term risk of cardiovascular death or 
myocardial infarction. Over a period of 3 years, 
the number needed to treat to prevent cardiovas-
cular death or myocardial infarction from occur-
ring in 1 patient is 37 patients, and the number 
needed to treat to prevent cardiovascular death, 
myocardial infarction, or ischemia-driven revas-
cularization from occurring in 1 patient is 13 
patients.
At least 70% stenosis in coronary arteries on 
visual estimation is routinely reported to be a 
standard criterion used in coronary angiography 
to establish the presence of angiographically 
significant coronary artery disease. Evidence of 
ischemia in the form of an FFR measurement of 
0.80 or less was required only in patients with 
moderate stenosis (50 to 69%), and only a small 
number of such patients were enrolled in the trial. 
Although it is possible that an FFR-based ap-
proach to guide nonculprit-lesion PCI could have 
reduced the number of PCI procedures among 
the patients included in the complete-revascular-
ization group, it is unclear how this strategy might 
have influenced the effect on hard clinical out-
comes. It is possible that angiographically signifi-
cant lesions associated with an FFR measurement 
Figure 1. Cumulative Incidence of the First and Second Coprimary Outcomes.
Panels A and B show Kaplan–Meier estimates of the cumulative incidence 
of the first coprimary outcome (death from cardiovascular causes or new 
myocardial infarction) and the second coprimary outcome (death from car‑
diovascular causes, new myocardial infarction, or ischemia‑driven revascu‑
larization), respectively. Insets show the same data on an enlarged y axis. 
PCI denotes percutaneous coronary intervention.
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Figure 2 (facing page). Subgroup Analyses of the First 
and Second Coprimary Outcomes.
P values for interaction have not been adjusted for mul‑
tiple comparisons. The SYNTAX (Synergy between PCI 
with Taxus and Cardiac Surgery) score is used to de‑
scribe the degree of angiographic complexity; a score 
of 0 indicates no angiographically significant disease, 
and higher scores indicate more extensive and com‑
plex coronary artery disease.
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of more than 0.80 may still contain morpho-
logic features consistent with unstable plaques, 
which confer an increased risk of recurrent events. 
At least two trials involving patients with STEMI 
and multivessel coronary artery disease that evalu-
ated an FFR-based approach to guide nonculprit-
lesion PCI did not show a reduction in the risk 
of cardiovascular death or myocardial infarc-
tion, although neither trial was powered for this 
outcome.16,17
In the COMPLETE trial, randomization was 
stratified according to the intended timing of 
nonculprit-lesion PCI. Investigators had to specify 
before randomization whether they intended to 
perform nonculprit-lesion PCI during the index 
hospitalization or after hospital discharge (with-
in 45 days) if the patient were to be assigned to 
the complete-revascularization group. We found 
a consistent benefit of complete revasculariza-
tion regardless of whether nonculprit-lesion PCI 
was performed earlier, during the index hospi-
talization, or later, several weeks after discharge. 
During the early period after STEMI, events re-
lated to the index infarction and culprit-lesion 
PCI probably accounted for a substantial propor-
tion of the events that occurred in both treat-
ment groups. The benefit of complete revascu-
larization seems to have emerged over the long 
term, with continued divergence of the Kaplan–
Meier curves for several years.
Limitations of our trial should be considered. 
We did not evaluate nonculprit-lesion PCI that 
was performed during the same procedure as 
that for the index culprit-lesion PCI for STEMI. 
Although cardiogenic shock was not an exclusion 
criterion, no patients with cardiogenic shock were 
enrolled in the trial and the results should not 
be extrapolated to such patients. Complete re-
vascularization was attained in more than 90% 
of the patients in the complete-revascularization 
group, and crossover to the nonculprit-lesion PCI 
strategy occurred in only 4.7% of the patients in 
the culprit-lesion-only PCI group. It is unclear 
whether the trial results would have been similar 
if complete revascularization had been observed 
in fewer patients or if the crossover criteria in 
the culprit-lesion-only PCI group had been more 
liberal.
In conclusion, the COMPLETE trial showed 
that, among patients with STEMI and multives-
sel coronary artery disease, a strategy of routine 
nonculprit-lesion PCI with the goal of complete 
revascularization, performed either during the 
index hospitalization or soon after discharge, 
was superior to a strategy of culprit-lesion-only 
PCI in reducing the risk of death from cardiovas-
cular causes or new myocardial infarction, as 
well as the risk of death from cardiovascular 
causes, new myocardial infarction, or ischemia-
driven revascularization, at a median follow-up 
of 3 years.
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